Skip to main content
Premium Trial:

Request an Annual Quote

UK MDx Shop Biofortuna Raises $1.6M, Feb 4, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Biofortuna said this week it has raised £1 million ($1.6 million), which it will use to develop a market for its diagnostic genotyping products and new products.

The funding is being provided by EV Tech, Catapult Venture Managers, Alliance Fund Managers, and Biofortuna's non-executive directors.

Biofortuna is developing genotyping and antibody screening tests directed at organ transplantation and management, blood banking, disease identification, microbiology, and pharmacogenomics.

Mike Bunce, CEO of Liverpool-based Biofortuna, said in a statement that the funding will allow the company to "continue to develop our groundbreaking freeze dried diagnostic kits and consolidate our position as a unique global innovator in clinical diagnostics and lyophilisation techniques."

The company raised $1.6 million in May to commercialize its in vitro PCR kits for HLA genotyping and human disease diagnosis.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.